3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Bronchogenic
1
Interventions
pembrolizumab
17
Carboplatin
10
Paclitaxel
7
Trastuzumab
5
Nivolumab
5
Gemcitabine
5
Early Intervention, Educational
5
Cyclophosphamide
5
Cisplatin
5
fludarabine
4
cemiplimab
4
Psychiatric Rehabilitation
4
Fluorouracil
4
Docetaxel
4
Counseling
4
Albumin-Bound Paclitaxel
4
tisotumab vedotin
3
belinostat
3
Radiotherapy
3
Polymerase Chain Reaction
3
Methods
3
Magnetic Resonance Spectroscopy
3
Gene Expression Profiling
3
Fluorodeoxyglucose F18
3
Biopsy
3
zimberelimab
2
ulixertinib
2
pertuzumab
2
palbociclib
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Interleukin-15
×
Gynecologic
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled